After coming up short in trials with two orexin type 2 receptor (OX2R) selective agonists, Takeda has scored with oveporexton,
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Let the orexin market begin: Takeda snags FDA approval for narcolepsy type 1 drug
Takeda approval ushers in new wave of sleep drugs
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
FDA Approves First-in-Class Narcolepsy Drug
Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
FDA approves new drug for narcolepsy type 1 symptoms - UPI.com
China Beats U.S. in Approving Takeda’s Breakthrough Narcolepsy Drug
Takeda's Orzeyful wins FDA approval as the first full-symptom narcolepsy type 1 drug, kicking off an orexin agonist race with…
An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that…
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Oveporexton treats more than symptoms, restores orexin signaling
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with…
The FDA approved a novel type of treatment for narcolepsy made by Takeda, backing a new drug class that scientists hope can be…
